Evaluation of melatonin as a potential drug for the improvement of clinical outcome, reduction of infarct size, sleep parameters and cognitive functions in post-stroke patients: A randomized, double blind, placebo-controlled study

Shiraz University of Medical Science0 个研究点目标入组 60 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Inclusion criteria :
•Clinical diagnosis of acute stroke in middle cerebral artery (MCA) territory established by MRI imaging; Males and females between18 to 70 years old; NIHSS score of 5-20 with a motor deficit of 2 or more; Level of consciousness less than 2 in NIHSS scale; Signed informed consent; More than 12 years education
•Exclusion criteria :
•Clinically relevant preexisting neurological deficit or previous CVA; Primary intracerebral hemorrhage; Coma; Negative swallow test; History of epilepsy or seizure at onset of stroke; Systolic BP is >220 mmHg, diastolic BP>120 ; Atrial fibrillation or other arrhythmias ; Ejection Fraction less than 30%; Aphasia; Malignancy or premalignant state within 5 years; Significant liver disease (Bilirubin > 20 mmoll/L); Respiratory failure (FEV1 < 1.5 L, pO2 < 70 in room air, pCO2 > 45); Psychiatric illness requiring hospital admission; Chronic kidney disease ; NIHSS> 20 ; Pregnancy or breast feeding; Inability to follow up the instructions of the study; Autoimmune disease; Steroid consumption

发起方

Shiraz University of Medical Science